International Journal of Radiation Oncology * Biology * Physics
Volume 53, Issue 2 , Pages 297-303 , 1 June 2002

Posttreatment prostate-specific antigen nadir highly predictive of distant failure and death from prostate cancer

  • Alexandra L Hanlon, Ph.D.

      Affiliations

    • Corresponding Author InformationReprint requests to: Alexandra L. Hanlon, Ph.D., Departments of Biostatistics and Radiation Oncology, Fox Chase Cancer Center, 7701 Burholme Ave., Philadelphia, USA PA 19111. Tel: (215) 728-3043; Fax: (215) 728-2553
    • Department of Biostatistics, Philadelphia, PA, USA
    • Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
  • ,
  • Hasmik Diratzouian, M.D.

      Affiliations

    • Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
  • ,
  • Gerald E Hanks, M.D.

      Affiliations

    • Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA

Received 20 June 2001 ,Revised 18 December 2001 ,Accepted 21 December 2001.

References 

  1. Prostate. In:  Fleming I,  Cooper J,  Henson D, et al. editor. AJCC cancer staging manual. Philadelphia: Lippincott-Raven; 1997;p. 219–224
  2. Iyer R, Hanlon A, Pinover W, et al.  Outcome evaluation of the 1997 AJCC staging system for prostate carcinoma treated by radiation therapy. Cancer. 1999;85:1816–1821
  3. Pinover W, Hanlon A, Hanks G, et al.  Defining the appropriate radiation dose for pretreatment PSA ≤10 ng/mL prostate cancer. Int J Radiat Oncol Biol Phys. 2000;47:649–654
  4. International Commission on Radiation Units and Measurements . ICRU Report No. 50. Prescribing Recording, and Reporting Photon Beam Therapy. Washington, DC: International Commission on Radiation Units and Measurements; 1993;
  5. Cox J, Grignon D, Kaplan R, et al.  Consensus statement (Guidelines for PSA following radiation therapy). Int J Radiat Oncol Biol Phys. 1997;37:1035–1041
  6. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:447–457
  7. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163–170
  8. Kalbfleisch JD, Ross LP. The statistical analysis of failure time data. New York: John Wiley & Sons; 1980;
  9. Pinover W, Hanlon A, Horwitz E, et al.  Validating a treatment policy for PSA failures following 3D conformal radiation therapy. Int J Radiat Oncol Biol Phys. 2000;48:206
  10. Davis J, Kolm P, Wright G, et al.  The durability of external beam radiation therapy for prostate cancer (Can it be identified?). J Urol. 1999;162:758–761
  11. Critz F, Levinson A, Williams W, et al.  Prostate specific antigen nadir achieved by men apparently cured of prostate cancer by radiotherapy. J Urol. 1999;161:1199–1205
  12. Greene G, Pisters L, Scott S, et al.  Predictive value of prostate specific antigen nadir after salvage cryotherapy. J Urol. 1998;160:86–90
  13. Crook J, Bahadur Y, Bociek R, et al.  The correlation of pretreatment prostate specific antigen and nadir prostate specific antigen with outcome assessed systematic biopsy and serum prostate specific antigen. Cancer. 1997;79:81–89
  14. Hanks GE, D’Amico A, Epstein B, et al.  Prostate-specific antigen doubling times in patients with prostate cancer (A potentially useful reflection of tumor doubling time). Int J Radiat Oncol Biol Phys. 1993;27:125–127
  15. D’Amico A, Hanks GE. Linear regressive analysis using PSA doubling time predicts tumor biology and clinical outcome in prostate cancer. Cancer. 1993;72:2638–2643
  16. Hanks GE, Hanlon AL, Lee WR, et al.  Pretreatment prostate specific doubling times (Clinical utility of this predictor of prostate cancer behavior). Int J Radiat Oncol Biol Phys. 1996;34:549–553
  17. Stamey TA, Yank N, Hay AR, et al.  Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987;317:909–917

PII: S0360-3016(02)02717-7

International Journal of Radiation Oncology * Biology * Physics
Volume 53, Issue 2 , Pages 297-303 , 1 June 2002